PET imaging of tumours with a 64 Cu labeled macrobicyclic cage amine ligand tethered to Tyr 3 -octreotate
- 30 October 2013
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 43 (3) , 1386-1396
Abstract
The use of copper radioisotopes in cancer diagnosis and radionuclide therapy is possible using chelators that are capable of binding CuII with sufficient stability in vivo to provide high tumour-to-background contrast. Here we report the design and synthesis of a new bifunctional chelator, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar), that forms copper complexes of exceptional stability by virtue of a cage amine (sarcophagine) ligand and a new conjugate referred to as SarTATE, obtained by the conjugation of MeCOSar to the tumour-targeting peptide Tyr3-octreotate. Radiolabeling of SarTATE with 64CuII, a radioisotope suitable for positron emission tomography (PET), was fast (∼20 min), easily performed at room temperature and consistently resulted in high radiochemical purity (>99%). In vitro and in vivo evaluation of 64CuSarTATE demonstrated its high selectivity for tumour cells expressing somatostatin receptor 2 (sstr2). Biodistribution and PET imaging comparisons were made between 64CuSarTATE and 64Cu-labeled DOTA-Tyr3-octreotate (64CuDOTATATE). Both radiopharmaceuticals showed excellent uptake in sstr2-positive tumours at 2 h post-injection. While tumour uptake of 64CuDOTATATE decreased significantly at 24 h, 64CuSarTATE activity was retained, improving contrast at later time points. 64CuSarTATE accumulated less than 64CuDOTATATE in the non-target organs, liver and lungs. The uptake of 64CuSarTATE in the kidneys was high at 2 h but showed significant clearance by 24 h. The new chemistry and pre-clinical evaluation presented here demonstrates that MeCOSar is a promising bifunctional chelator for Tyr3-octreotate that could be applied to a combined imaging and therapeutic regimen using a combination of 64Cu- and 67CuSarTATE complexes, owing to improved tumour-to-non-target organ ratios compared to 64CuDOTATATE at longer time points.Keywords
This publication has 55 references indexed in Scilit:
- The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide TreatmentJournal of Nuclear Medicine, 2011
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancyCancer Imaging, 2010
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- Copper(ii) cyclam-based complexes for radiopharmaceutical applications: synthesis and structural analysisDalton Transactions, 2007
- Ultrastable complexes for in vivo use: a bifunctional chelator incorporating a cross-bridged macrocycleChemical Communications, 2004
- Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) ComplexesJournal of the American Chemical Society, 2000
- In Vivo Transchelation of Copper-64 from TETA-Octreotide to Superoxide Dismutase in Rat LiverBioconjugate Chemistry, 2000
- In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. a new somatostatin analog with improved target tissue uptakeNuclear Medicine and Biology, 1999
- Comparison of Four 64Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted RadiotherapyJournal of Medicinal Chemistry, 1999